Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASTED is an investigator-developed, oral fixed-dose antioxidant vitamin-and-mineral supplement for thyroid eye disease. It combines beta-carotene, vitamin C, vitamin E as alpha-tocopherol acetate, calcium phosphate dihydrate, zinc oxide, copper gluconate, sodium selenite, and nicotinamide. Its proposed therapeutic rationale is to reduce oxidative stress and support endogenous antioxidant defenses implicated in thyroid eye disease; it has no single defined molecular drug target. ASTED was evaluated in randomized placebo-controlled phase 2/3 studies in mild and moderate-to-severe thyroid eye disease sponsored by Iran University of Medical Sciences. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02393183))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ASTED.